Coulter Partners was delighted to partner recently with Optimapharm to secure the appointment of Dr. Andrew Copestake as Chief Executive Officer. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors. Optimapharm is a contract research organization managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe.
- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment
- Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills
- New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics
The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.
Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors.
Coulter Partners was delighted to partner once again with Albumedix, the world leader in recombinant human albumin (rAlb), to secure the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy.
TWO businesses based in The Biosphere on Newcastle Helix have been awarded funding to accelerate their innovations to support the global fight against the COVID-19. Innovate UK, the UK’s innovation agency has awarded ExplantLab and Atelerix almost £50,000 each to fast track their ideas and research.
Locate Bio Ltd (“Locate”), an orthobiologics company pursuing multiple high value spinal opportunities, announced that John von Benecke has been appointed CEO to drive Locate’s lead program for spinal fusion and continue to build out its spinal pipeline.
Coulter Partners was very pleased to partner recently with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner brings more than 20 years of experience leading multiple pharmaceutical development programs from discovery through approval and launch, in both large and small pharmaceutical companies.
The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. Eisai join AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the bio-incubator programme